Tag: aim:summ

August 16, 2018

Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection

Summit Therapeutics (NASDAQ:SMMT, AIM:SUMM), a leader in antibiotic innovation, today announces that it has been awarded an additional $12 million...
June 27, 2018

Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint

Summit Therapeutics (AIM:SUMM, NASDAQ:SMMT) announces PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment...